Patient-Reported Symptom Control of Diarrhea and Flushing in Patients with Neuroendocrine Tumors Treated with Lanreotide Depot/Autogel: Results from a Randomized, Placebo-Controlled, Double-Blind and 32-Week Open-Label Study Article

authors

publication date

  • January 1, 2018

webpage

published in

keywords

  • Carcinoid syndrome
  • Clinical trial
  • Lanreotide depot
  • Neuroendocrine tumor
  • Quality of life
  • autogel

start page

  • 16

end page

  • 24

volume

  • 23

issue

  • 1